Clinical Trial Update: A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the investigational therapy LTI-03 in newly diagnosed Idiopathic Pulmonary Fibrosis has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• LTI-03

Snippet

Sponsor: Rein Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2025-07-31